Compare Novavax Inc (NVAX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs United Microelectronics Corp — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while United Microelectronics Corp trades at $22.31 (market cap $54.48B). The key difference: United Microelectronics Corp is far larger — about 32.4× Novavax Inc's market cap, and United Microelectronics Corp pays a 1.84% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | UMC | |
|---|---|---|
Market Cap | $1.68B | $54.48B |
Sector | Health | Technology |
52-Week High | $11.19 | $28.02 |
52-Week Low | $6.22 | $6.76 |
Enterprise Value | $1.26B | $51.52B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
UMC trades at $21.82, up 5.06% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.54 versus $0.16 expected, and announced a $0.41 dividend payable in August 2026. Revenue trends show recovery, with 2026 projections at $250.7B and net income margin improving to 32.75%.
Outlook is positive due to earnings momentum and AI expansion plans, but risks include competitive pressures and volatility from AI spending concerns. Analyst consensus is mixed with 27% buy ratings, suggesting cautious optimism amid high valuation multiples like P/E of 20.96.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
